Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevnar 13

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Fourth quarter results overshadowed by spin off announcement

- PMLiVE

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Alzheimer's patients typically experience poor sleep

- PMLiVE

FDA accepts priority review for Merck’s antibiotic combo Recarbrio

If approved would provide new option for hard-to-treat infections

- PMLiVE

Vyndaqel a bright spot as Pfizer comes under pressure

Faces a challenging period as big brands experience a slowdown

- PMLiVE

Pfizer signs $507m cancer deal with Effector Therapeutics

Collaboration is focused on research into evasive oncogenic target

- PMLiVE

Keytruda claims first place in bladder cancer race

Stays ahead of rivals in the PD-1/PD-L1 inhibitor class

- PMLiVE

Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Confirmatory trial strengthens claim in therapy area

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

- PMLiVE

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Sets stage for lower-cost competition to big-selling drug

- PMLiVE

FDA follows EMA with approval of Merck’s Ebola vaccine

First to be approved in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links